Pharmerica (PMC) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Oppenheimer sees AI software winners as focus shifts to ROI
- Arm Holdings falls as CFO stock sale weighs on sentiment
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
Acquisitions, Specialty and Brand Inflation Drive Pharmerica's (PMC) 3Q Beat; Cowen Reiterates Outperform
November 6, 2015 1:45 PM ESTCowen reiterated an Outperform rating and $39.00 price target on PharMerica (NYSE: PMC) following the company's 3Q earnings report. PMC reported 3Q adj. EPS of $0.39, ahead of consensus of $0.36. Revenue of $498.8M was up 6% y/y and also beat consensus of $480.3M, driven by recent... More
